MediWound Secures €16.25 Million in Funding to Accelerate Development of EscharEx® for Diabetic Foot Ulcers
MediWound Ltd. (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced a major funding milestone through the European Innovation Council (EIC) Accelerator program. The company has been awarded €16.25 million to propel the clinical development of EscharEx®, a groundbreaking biologic aimed at treating diabetic foot ulcers (DFUs). The EIC’s decision to support…